Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER - Free Report) in a research note published on Tuesday,Benzinga reports.

OMER has been the subject of a number of other reports. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, April 1st. StockNews.com cut shares of Omeros from a "hold" rating to a "sell" rating in a research note on Friday, March 21st. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Price Performance

Shares of NASDAQ OMER traded down $0.30 during trading hours on Tuesday, reaching $7.06. The stock had a trading volume of 802,194 shares, compared to its average volume of 552,480. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The business's fifty day moving average is $8.56 and its two-hundred day moving average is $7.65. The company has a market cap of $409.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.35.

Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period in the prior year, the company posted ($0.15) EPS. Sell-side analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of hedge funds have recently modified their holdings of OMER. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 1,110 shares in the last quarter. Truvestments Capital LLC lifted its position in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after buying an additional 2,317 shares during the last quarter. Finally, Cerity Partners LLC increased its position in shares of Omeros by 9.9% in the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 2,600 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.